Strota/ Newsroom/ 2026-09-28

QMSMEDI (QMSMEDI): Acquisition / M&A

Strota Newsroom · session of 2026-09-28 · 28 Sep 11:22 · QMSMEDI stock page →

QMS Medical Allied Services Limited has informed the Exchange regarding a press release dated September 28, 2026, titled… Historically, acquisition / m&a events have moved QMSMEDI-type stocks in the bullish direction 48.9% of the next sessions (n=141).

QMS Medical Allied Services Limited informed the exchange on 28 Sep 11:22 about a press release titled that QMS Medical Allied Services is to acquire Beamoptics Scientific, a Pune-based diagnostics and analytical deep-tech company. The pack classifies the event as Acquisition / M&A with a bullish bias. A related acquisition notice also appears on 2026-09-27 in the catalysts list, so the company has been in an active disclosure cluster around this deal.

Acquisition-type events in the reaction sample of n 141 show win_rate 48.9 percent and net_edge_pct 0.213 — again a near-neutral historical average rather than a prediction. The Nifty was down 1.56 percent on the as_of date. Valuation fields list mcap_cr 399.0, pe 39.33, pb 6.96, eps 5.25 and div_yield_pct 0.24.

News around the name includes an older simplywall.st note on an approaching ex-dividend date and a Kalkine India item on a HEINE exclusive distribution deal from weeks earlier. Those are separate threads from the Beamoptics acquisition headline and are not packed as same-day price drivers.

What the pack establishes is a stated plan to acquire Beamoptics Scientific disclosed on 28 Sep 11:22, a small-cap valuation footprint around mcap_cr 399.0, and a flat acquisition base rate on n 141. What it does not establish is the purchase price, funding mix, or earnings impact of Beamoptics — none of those figures appear in the pack.

The catalyst

QMS Medical Allied Services Limited has informed the Exchange regarding a press release dated September 28, 2026, titled "QMS Medical Allied Services to acquire Beamoptics Scientific a Pune-based diagnostics and Analytical deep-tech company". (filing · NSE)

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

QMSMEDI right now

P/E 39.33. Full QMSMEDI analysis →

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.